Blood eosinophil-guided oral prednisolone for COPD exacerbations in primary care in the UK (STARR2): a non-inferiority, multicentre, double-blind, placebo-controlled, randomised controlled trial
Sanjay Ramakrishnan(Oxford BioMedica (United Kingdom)), Mona Bafadhel(National Institute for Health and Care Research), Robin Fox(Bicester Community Hospital), Simon Cartwright(Horse Hospital), Helen Jeffers(University of Oxford), Mahdi Mahdi(National Institute for Health and Care Research), Samantha Thulborn(University of Oxford), David Copping, Christine A’Court(University of Oxford), Ian Binnian, Stephen Bright(Edith Cowan University), Richard EK Russell(The University of Queensland), Joanne Davies(University of Oxford), Christopher Davies(Foundation for Water Research), Alison Law(The White House), Victoria Glover(Horse Hospital), Adam Jones, B Langford-Wiley(University of Oxford)
Cited by 70
Related Papers
Beyond Adoption: A New Framework for Theorizing and Evaluating Nonadoption, Abandonment, and Challenges to the Scale-Up, Spread, and Sustainability of Health and Care Technologies
|Journal of Medical Internet Research|2017|2.7k
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts
|New England Journal of Medicine|2023|452
Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial
|The Lancet Respiratory Medicine|2021|434
Benralizumab for the Prevention of COPD Exacerbations
|New England Journal of Medicine|2019|329